Mobile website
Clinical Research
Clinical efficacy of chemotherapy combined with cytokine-induced killer cell treatment after curative resection for gastric cancer patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To estimate the clinical efficacy of chemotherapy combined with cytokine-induced killer cell（CIK）treatment after curative resection for gastric cancer patients. Methods: 65 gastric cancer patients treated with chemotherapy combined with CIK (chemotherapy combined with CIK group) and 130 patients treated with chemotherapy only after radical gastrectomy (chemotherapy-only group) were included in this study (from March 1999 to December 2007 in Affiliated Cancer Hospital of Tianjin Medical University). The survival rate and live time was compared between two groups. The receiver operating characteristic (ROC) was analyzed, and the periodicity of chemotherapy and the frequency of CIK treatment was determined. The survival curve was made by Kaplan-Meier method, and the survival difference was compared by Log-rank test. Results: The overall 3- and 5-year survival rates of the chemotherapy combined with CIK group were slightly higher than those of the chemotherapy-only group, and without significant difference (60% vs 47%, 55% vs 23%, P>005). The 3- and 5-year progression free survival rates of the chemotherapy combined with CIK group were lower than those of the chemotherapy-only group (48% vs 31%, 47% vs 20%, P<0.05). The median overall survival (OS) of chemotherapy combined with CIK group was 96 months, which was longer than that of 32 months in the chemotherapy-only group (P=0.001). The median progression free survival (PFS) was 36 months in the chemotherapy combined with CIK group and was longer than that of 23 months in the chemotherapy-only group (P=0.011). In univariate analysis, the TNM stage, chemotherapy cycle and CIK frequency were related to OS of the patients; the TNM stage, the modes of surgery and CIK frequency were related to PFS of patients. Multivariate analysis revealed that the chemotherapy cycle independently influenced OS. However, CIK frequency was an independent risk factor of both OS and PFS. Conclusion: OS is significantly longer in the gastric patients treated with chemotherapy combined with CIK than the patients treated with chemotherapy alone, and the higher CIK frequency shows more clinical benefits.
Keywords:
Project Supported:
Project supported by National Natural Science Foundation of China（No.30901754, No.20090133）
Clc Number:
